Foghorn Therapeutics Stock Price To Earning

FHTX Stock

USD 7.90 0.06 0.77%

Foghorn Therapeutics fundamentals help investors to digest information that contributes to Foghorn Therapeutics' financial success or failures. It also enables traders to predict the movement of Foghorn Stock. The fundamental analysis module provides a way to measure Foghorn Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Foghorn Therapeutics stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Foghorn Therapeutics Company Price To Earning Analysis

Foghorn Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Foghorn Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Foghorn Therapeutics is extremely important. It helps to project a fair market value of Foghorn Stock properly, considering its historical fundamentals such as Price To Earning. Since Foghorn Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Foghorn Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Foghorn Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Long Term Debt	Short Term Debt	Net Receivables	Short Term Investments	Capital Surpluse
Total Assets		0.55	0.73	-0.48	-0.8	0.78	0.89	0.93	0.49	1.0	0.99	0.92	0.91	0.54	-0.33	0.87	0.65	0.43	0.73
Total Stockholder Equity	0.55		0.91	-0.09	-0.06	0.1	0.47	0.23	1.0	0.52	0.57	0.48	0.59	0.1	0.31	0.18	0.53	-0.14	-0.08
Net Tangible Assets	0.73	0.91		-0.06	-0.41	0.41	0.71	0.46	0.89	0.7	0.73	0.75	0.83	0.11	-0.09	0.51	0.51	0.0	0.28
Net Debt	-0.48	-0.09	-0.06		0.41	-0.45	-0.36	-0.55	-0.05	-0.48	-0.48	-0.38	-0.33	-0.99	-0.06	-0.33	0.02	-0.88	-0.37
Retained Earnings	-0.8	-0.06	-0.41	0.41		-0.95	-0.84	-0.88	-0.01	-0.79	-0.75	-0.89	-0.83	-0.51	0.74	-0.95	-0.21	-0.64	-0.96
Accounts Payable	0.78	0.1	0.41	-0.45	-0.95		0.92	0.86	0.07	0.76	0.71	0.9	0.85	0.56	-0.55	0.91	0.16	0.66	0.91
Long Term Debt	0.89	0.47	0.71	-0.36	-0.84	0.92		0.85	0.44	0.86	0.84	0.98	0.97	0.47	-0.34	0.89	0.39	0.46	0.78
Total Liab	0.93	0.23	0.46	-0.55	-0.88	0.86	0.85		0.16	0.94	0.92	0.86	0.81	0.62	-0.41	0.94	0.56	0.56	0.88
Net Invested Capital	0.49	1.0	0.89	-0.05	-0.01	0.07	0.44	0.16		0.47	0.51	0.44	0.55	0.06	0.34	0.12	0.48	-0.17	-0.13
Total Current Assets	1.0	0.52	0.7	-0.48	-0.79	0.76	0.86	0.94	0.47		1.0	0.9	0.89	0.54	-0.32	0.87	0.68	0.42	0.73
Net Working Capital	0.99	0.57	0.73	-0.48	-0.75	0.71	0.84	0.92	0.51	1.0		0.87	0.87	0.53	-0.28	0.83	0.71	0.39	0.68
Common Stock	0.92	0.48	0.75	-0.38	-0.89	0.9	0.98	0.86	0.44	0.9	0.87		0.99	0.47	-0.45	0.91	0.38	0.49	0.82
Property Plant Equipment	0.91	0.59	0.83	-0.33	-0.83	0.85	0.97	0.81	0.55	0.89	0.87	0.99		0.43	-0.39	0.86	0.42	0.42	0.73
Current Deferred Revenue	0.54	0.1	0.11	-0.99	-0.51	0.56	0.47	0.62	0.06	0.54	0.53	0.47	0.43		-0.01	0.41	0.0	0.91	0.45
Short Long Term Debt	-0.33	0.31	-0.09	-0.06	0.74	-0.55	-0.34	-0.41	0.34	-0.32	-0.28	-0.45	-0.39	-0.01		-0.59	0.09	-0.32	-0.68
Short Term Debt	0.87	0.18	0.51	-0.33	-0.95	0.91	0.89	0.94	0.12	0.87	0.83	0.91	0.86	0.41	-0.59		0.44	0.47	0.96
Net Receivables	0.65	0.53	0.51	0.02	-0.21	0.16	0.39	0.56	0.48	0.68	0.71	0.38	0.42	0.0	0.09	0.44		-0.28	0.22
Short Term Investments	0.43	-0.14	0.0	-0.88	-0.64	0.66	0.46	0.56	-0.17	0.42	0.39	0.49	0.42	0.91	-0.32	0.47	-0.28		0.58
Capital Surpluse	0.73	-0.08	0.28	-0.37	-0.96	0.91	0.78	0.88	-0.13	0.73	0.68	0.82	0.73	0.45	-0.68	0.96	0.22	0.58

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Foghorn Therapeutics

Foghorn Retained Earnings

Retained Earnings

(447.99 Million)

Foghorn Therapeutics reported Retained Earnings of (471.56 Million) in 2023

Based on the latest financial disclosure, Foghorn Therapeutics has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earning for all United States stocks is 100.0% higher than that of the company.

Foghorn Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Foghorn Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Foghorn Therapeutics could also be used in its relative valuation, which is a method of valuing Foghorn Therapeutics by comparing valuation metrics of similar companies.

Foghorn Therapeutics is currently under evaluation in price to earning category among its peers.

Foghorn Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Foghorn Therapeutics from analyzing Foghorn Therapeutics' financial statements. These drivers represent accounts that assess Foghorn Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Foghorn Therapeutics' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	667.2M	745.8M	850.1M	265.4M	270.7M	257.2M
Enterprise Value	668.8M	735.0M	807.3M	(28.9M)	235.5M	223.7M

Foghorn Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Foghorn Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Foghorn Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Foghorn Fundamentals

	Return On Equity	-4.7
	Return On Asset	-0.2
	Operating Margin	(3.05) %
	Current Valuation	210.86 M
	Shares Outstanding	55.59 M
	Shares Owned By Insiders	18.98 %
	Shares Owned By Institutions	72.10 %
	Number Of Shares Shorted	1.13 M
	Price To Book	10.71 X
	Price To Sales	17.21 X
	Revenue	34.16 M
	Gross Profit	(86.39 M)
	EBITDA	(104.45 M)
	Net Income	(98.43 M)
	Cash And Equivalents	373.5 M
	Cash Per Share	8.94 X
	Total Debt	45.07 M
	Debt To Equity	2.19 %
	Current Ratio	6.84 X
	Book Value Per Share	(0.51) X
	Cash Flow From Operations	(118.11 M)
	Short Ratio	8.53 X
	Earnings Per Share	(1.85) X
	Target Price	16.0
	Number Of Employees	116
	Beta	3.15
	Market Capitalization	439.19 M
	Total Asset	285.92 M
	Retained Earnings	(471.56 M)
	Working Capital	181.75 M
	Net Asset	285.92 M

About Foghorn Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Foghorn Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Foghorn Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Foghorn Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC